| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 1/6 |
| Past Performance | 3/6 |
| Financial Health | 5/6 |
| Dividends | 2/6 |
Rewards
Risk Analysis
Zhejiang Shouxiangu Pharmaceutical Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥25.29 |
| 52 Week High | CN¥48.50 |
| 52 Week Low | CN¥23.07 |
| Beta | 0.37 |
| 1 Month Change | 0.92% |
| 3 Month Change | -13.18% |
| 1 Year Change | -45.85% |
| 3 Year Change | -12.30% |
| 5 Year Change | -17.81% |
| Change since IPO | 97.82% |
Recent News & Updates
Recent updates
Shareholder Returns
| 603896 | CN Personal Products | CN Market | |
|---|---|---|---|
| 7D | 3.4% | 6.1% | 1.6% |
| 1Y | -45.8% | -23.0% | -15.1% |
Return vs Industry: 603896 underperformed the CN Personal Products industry which returned -23% over the past year.
Return vs Market: 603896 underperformed the CN Market which returned -15.1% over the past year.
Price Volatility
| 603896 volatility | |
|---|---|
| 603896 Average Weekly Movement | 6.2% |
| Personal Products Industry Average Movement | 6.2% |
| Market Average Movement | 8.8% |
| 10% most volatile stocks in CN Market | 12.6% |
| 10% least volatile stocks in CN Market | 5.3% |
Stable Share Price: 603896 has not had significant price volatility in the past 3 months.
Volatility Over Time: 603896's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1997 | 1,051 | Zhen-Yu Li | www.sxg1909.com |
Zhejiang Shouxiangu Pharmaceutical Co., Ltd. researches, develops, and sells Chinese medicine products. It offers ganoderma lucidum spore powder, dendrobium officinale and ganoderma lucidum extract, dendrobium officinale granules, saffron extract, crocus sativus, and other health products. Zhejiang Shouxiangu Pharmaceutical Co., Ltd.
Zhejiang Shouxiangu Pharmaceutical Co., Ltd. Fundamentals Summary
| 603896 fundamental statistics | |
|---|---|
| Market cap | CN¥5.01b |
| Earnings (TTM) | CN¥287.01m |
| Revenue (TTM) | CN¥864.06m |
17.5x
P/E Ratio5.8x
P/S RatioIs 603896 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 603896 income statement (TTM) | |
|---|---|
| Revenue | CN¥864.06m |
| Cost of Revenue | CN¥147.25m |
| Gross Profit | CN¥716.81m |
| Other Expenses | CN¥429.80m |
| Earnings | CN¥287.01m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
Apr 26, 2024
| Earnings per share (EPS) | 1.45 |
| Gross Margin | 82.96% |
| Net Profit Margin | 33.22% |
| Debt/Equity Ratio | 32.5% |
How did 603896 perform over the long term?
See historical performance and comparison